RecruitingEarly Phase 1NCT07634640
Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction
Omega-3 Fatty Acids and Myocardial Inflammation in HFpEF: Preliminary Data and Next Steps
Sponsor
University of Florida
Enrollment
70 participants
Start Date
Nov 3, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Subjects undergo a gadolinium-based CMR followed by an iron infusion and then a repeat CMR in 72 hours
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Ferumoxytol infusion for people with heart failure with preserved ejection fraction (hfpef). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 85 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGFerumoxytol infusion
Ferumoxytol infusion followed by cardiac MRI
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07634640
Related Trials
ELEVATE-HFpEF Clinical Study
NCT0667884146 locations
The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction
NCT067684371 location
Coronary Artery Stents in Heart Failure With Preserved Ejection Fraction
NCT075604361 location
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT0721951121 locations
Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR
NCT071851001 location